JDB175, a selective BTK inhibitor with oral bioavailability, demonstrates excellent penetration through the blood-brain barrier. It exhibits potent activity against central nervous system lymphoma in a mouse model, with no apparent toxicity. JDB175 effectively suppresses human lymphoma cell proliferation by inhibiting the BTK signaling pathway, induces cell cycle arrest, and promotes apoptosis[1].

DB175（15-40 μM，48小时）能在Namalwa和Raji细胞中有效抑制BTK磷酸化，并调节细胞周期调控蛋白，具体表现为cyclin D1和CDK2表达降低，同时P21表达上升[1]。

JDB175（10 mg/kg，口服，0.5h）在大鼠体内表现出强大的血脑屏障穿透能力，并能有效抑制中枢神经系统淋巴瘤[1]。此外，JDB175（150 mg/kg，口服，3天）在裸鼠的中枢神经系统淋巴瘤肿瘤模型中显示出显著的抗肿瘤效果和高安全性[1]。